Ankylosing Spondylitis Market

Report Highlights

The report broadly covers different types of ankylosing spondylitis based on their drug type or route of administration. Furthermore, the scope of the report also covers the impact of COVID-19 and drivers and challenges for Ankylosing Spondylitis market.

The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each drug, treatment type, molecule, route of administration, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional ankylosing spondylitis markets; it explains the major market drivers of the global ankylosing spondylitis industry, current trends within the industry, major applications, and the regional dynamics of the global ankylosing spondylitis market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global ankylosing spondylitis market.

Report Includes

• 47 tables and 55 figures
• An up-to-date analysis of the Global Ankylosing Spondylitis Market.
• Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
• Estimation of market size and revenue forecast for global ankylosing spondylitis market, and corresponding market share analysis by drug, treatment type, molecule, route of administration, end-user, and region.
• Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Ankylosing Spondylitis, identification of the companies that are best positioned to meet this demand.
• In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
• Identification of promising new drugs, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
• Impact of COVID-19 on the Ankylosing Spondylitis Market as compared to overall global economy.
• Insight into the growth development strategies of major Ankylosing Spondylitis manufacturers and their key competitive landscape
• Descriptive company profiles of the leading market participants, including AbbVie, Inc., Amgen Inc., Pfizer, Inc., Novartis AG, Eli Lilly and Company, UCB, Inc., Johnson & Johnson, Merck & Co., Inc., and others.

Summary

Ankylosing spondylitis is an inflammatory autoimmune disease which cause the small bone spines and vertebrae to fuse together thereby, affecting the spine and making it less flexible. The disease is commonly known as Bechterew disease is an unusual type of arthritis.

The spread of ankylosing spondylitis could be from spine to the neck region also damaging the adjacent joints. As of now, there is no permanent cure for this disease but, medication and proper exercise could help in easing out the pain.

Some of the common symptoms of the disease are stiffness in joints along with, fatigue, fever, loss of appetite, many others. Ankylosing spondylitis has a global prevalence of about 0.1 to 0.5%. There is no specific age for this disease however, the disease mostly occurred during the age group of 19 to 40 years.